Showing 2911-2920 of 5685 results for "".
- State Strips Ex-USC Medical School Dean of License, Citing ‘An Appalling Lack of Judgment’https://modernod.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/The California state agency that regulates physicians ordered USC’s former medical school dean stripped of his license to practice medicine, citing “an appalling lack of judgment” in his use of drugs an
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- Novartis Announces Intention to Spinoff Alcon Into Standalone Companyhttps://modernod.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/After months of speculation, Novartis confirmed on Friday its intention to spinoff Alcon into a separately-traded standalone company. The major transaction would enable Novartis to focus on bringing new drugs to market, while allowing Alcon to focus on its core offerings in the surgical and visio
- Retinal Thinning Tied to Cognitive Declinehttps://modernod.com/news/retinal-thinning-tied-to-cognitive-decline/2480058/Thinning of the eye’s retinal nerve fiber layer (RNFL) appears to be a strong predictor of cognitive decline, new research shows, according to a report in Medscape. Investigators found healthy individuals with RNFL thinning w
- Novaliq’s NovaTears Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealandhttps://modernod.com/news/novaliqs-novatears-treatment-for-evaporative-dry-eye-disease-is-now-available-across-australia-and-new-zealand/2480059/Novaliq announced that NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction (MGD), is now also available in Australia. Just 8 months after launching in New Zealand, AFT Pharmaceuticals Ltd (AFT) has achieved registration of NovaTears in Australia. AFT, a